Neoleukin Therapeutics to Present at Canaccord Genuity Horizons in Oncology Conference

SEATTLE, April 07, 2022 (GLOBE NEWSWIRE) — Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design

de novo

protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will participate in a fireside chat at the Canaccord Genuity Horizons in Oncology Conference on Thursday, April 14, 2022 at 12:00 p.m. Eastern.

The webcast presentation can be accessed from the investors section of the Neoleukin website at


http://investor.neoleukin.com/events


. An archived replay will also be available on the company website for at least 30 days following the event.


About Neoleukin Therapeutics, Inc.

Neoleukin is a biopharmaceutical company creating next generation immunotherapies for cancer, inflammation and autoimmunity using

de novo

protein design technology. Neoleukin uses sophisticated computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins. Neoleukin’s lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to improve tolerability and activity by eliminating the alpha receptor binding interface. For more information, please visit the Neoleukin website:


www.neoleukin.com


.


Contacts:


Media


Julie Rathbun

206-769-9219

[email protected]


Investors


Solebury Trout

Alexandra Roy

617-221-9197

[email protected]


Primary Logo